Text Size

Predictive Value of Dynamic Contrast Enhancement MRI on a Cerebral Tumor Response to Gamma Knife Treatment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Universitaire de Sherbrooke.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Universitaire de Sherbrooke
ClinicalTrials.gov Identifier:
NCT00156585
First received: September 7, 2005
Last updated: February 6, 2006
Last verified: September 2005
History of Changes
  Purpose

Hypothesis: the pattern of MRI contrast enhancement after gadolinium injection is different in tumors that respond well to gamma knife.

We are going to acquire sequential T1-weighted images of brain lesions before, during and after injection of Gd-DTPA. This will be repeated before and after a treatment with gamma knife. We will then analyse our results to see if there are common enhancement characteristics between lesions that will respond well to the radiosurgery treatment.


Condition
Cerebral Metastases

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Prospective Study of Predictive Value of Dynamic Contrast Enhancement Magnetic Resonance Imaging With Gadolinium on the Response of a Cerebral Tumor to a Treatment With Gamma Knife

Resource links provided by NLM:

MedlinePlus related topics: Cancer MRI Scans
U.S. FDA Resources

Further study details as provided by Universitaire de Sherbrooke:

Estimated Enrollment: 30
Study Start Date: August 2005
Estimated Study Completion Date: June 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient with intracerebral lesion benign or malignant wich are not concerned by the exclusion criteria

Exclusion Criteria:

  • Pancranial radiotherapy
  • Residual postop lesion
  • Gliomas
  • Patients < 18 years old
  • Anterior allergic reaction to gadolinium
  • Claustrophobia.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00156585

Contacts
Contact: Brendan Kenny, MD 1-819-346-1110 ext 14962
Contact: Chenard Jean, MD 1-819-346-1110 ext 14962

Locations
Canada, Quebec
Faculté de médecine, Université de Sherbrooke Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Chenard Jean, MD     1-819-346-1110 ext 14962        
Contact: Martin Lepage, PhD     1-819-346-1110 ext 11867        
Principal Investigator: Chenard Jean, MD            
Sponsors and Collaborators
Universitaire de Sherbrooke
Investigators
Principal Investigator: Jean Chenard, MD University of Sherbrooke
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00156585     History of Changes
Other Study ID Numbers: 05-063
Study First Received: September 7, 2005
Last Updated: February 6, 2006
Health Authority: Canada: Health Canada

Keywords provided by Universitaire de Sherbrooke:
cerebral metastases
dynamic contrast enhanced magnetic resonance imaging
DCE-MRI
gamma knife

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes

ClinicalTrials.gov processed this record on May 23, 2013